1380 RESULTS
CONFERENCE COVERAGE 2024-04-12 Conference Coverage As neuronal supporters and immune surveyors, astrocytes and microglia are no mere bystanders to the neuronal mayhem that unfolds in Alzheimer’s disease. At the AD/PD meeting, held March 5-9 in Lisbon, scientists presented new twists on
CONFERENCE COVERAGE 2024-04-12 Conference Coverage Scientists are expanding strategies for targeting misfolded tau. At this year’s AD/PD conference, held March 5 to 9 in Lisbon, Portugal, speakers highlighted a protein modification approach—sumoylation. This post-translational modifica
CONFERENCE COVERAGE 2024-03-28 Conference Coverage With people now being treated with amyloid immunotherapy in the clinic, reducing the risk of ARIA has taken on a new sense of urgency. This inflammatory side effect occurs in people who have amyloid in small to medium-sized blood vesse
CONFERENCE COVERAGE 2024-03-23 Conference Coverage At this year’s AD/PD meeting, held March 5-9 in Lisbon, Portugal, no splashy Phase 3, or even Phase 2, data on tau-targeted therapies wowed attendees. Still, Phase 1 and preclinical data showcased a variety of therapeutic approaches th
CONFERENCE COVERAGE 2024-03-22 Conference Coverage Old drugs die hard. Despite a string of negative Phase 3 trials, HMTM, a derivative of the malaria drug methylene blue, resurfaced again at AD/PD 2024, held March 5-9 in Lisbon, Portugal. TauRx CEO Claude Wischik reported results from
CONFERENCE COVERAGE 2024-03-15 Conference Coverage A record 4,700 people from 70 countries attended the 18th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 5 to 9 in Lisbon, Portugal. Those who attended this hybrid meeting in person sometimes packed rooms
CONFERENCE COVERAGE 2023-12-19 Conference Coverage At the second annual Holloway Summit, held November 30 to December 1 in Miami, frontotemporal dementia researchers showcased the current state of knowledge in finding biomarkers that identify different underlying pathologies of the dis
CONFERENCE COVERAGE 2023-12-19 Conference Coverage Because frontotemporal dementia is a rare disease, it has not gotten nearly the attention or research dollars of its big cousin, Alzheimer’s. As a result, progress in the field has lagged behind, particularly with regard to biomarkers.
CONFERENCE COVERAGE 2023-12-01 Conference Coverage The blood-based p-tau marker field is getting pretty busy. In addition to existing tests by Fujirebio, Lilly, Janssen, and Meso Scale Discovery, C2N debuted a new CLIA-approved mass spectrometry-based test last August, while ALZPath In
CONFERENCE COVERAGE 2023-11-30 Conference Coverage Feel like your head is spinning? Like a little blood sample in a centrifuge, perhaps? No need to panic. It just means you are straining, like the rest of us, to keep up with the Alzheimer's disease plasma biomarker development fie
CONFERENCE COVERAGE 2023-11-28 Conference Coverage The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more accurately reflecting the underlying b
CONFERENCE COVERAGE 2023-11-21 Conference Coverage When COVID forced much of the world into virtual work, dementia scientists sped up their ongoing adaptation of cognitive assessments to digital versions (Dec 2021 conference news). How are they performing now? At the Clinical Trials in
CONFERENCE COVERAGE 2023-11-18 Conference Coverage As researchers parse what makes amyloid immunotherapy work, one answer keeps bubbling up: Take out all plaque quickly, so that clinical benefits have time to show up. At last month’s Clinical Trials on Alzheimer’s Disease conference, h
CONFERENCE COVERAGE 2023-11-17 Conference Coverage Can γ-secretase modulators stage a comeback? Scientists led by Irene Gerlach at F. Hoffmann-La Roche, Basel, Switzerland, are banking on it. At this year’s CTAD meeting, held October 24-27 in Boston, they reported that RG6289, a second
CONFERENCE COVERAGE 2023-11-11 Conference Coverage Current amyloid immunotherapies poorly enter the brain, with only one in a thousand antibodies getting through. For several years, researchers have been exploring alternate delivery methods that could allow for lower dosing and higher
